Smmay Three human rhabdomyosarcoma cell lines were used to investigate the presence of autocrine loops based on the production of insulin-like growth factor (IGF)-II, basic fibroblast growth factor (bFGF) and epidermal growth factor (EGF)jtransforming growth factor (TGF)-a and of their corresponding receptors, and whether these loops affect cell proliferation and myogenic differentiation. 
Rhabdomyosarcoma. a tumour of the skeletal muscle which can retain myogenic differentiative ability in vitro (Garvin et al., 1986; Nanni et al., 1986; Gabbert et al., 1988; Aguanno et al., 1990) , is a suitable model to study autocrine loops involved in proliferation and or differentiation of solid tumours, and to set up a differentiation therapy approach (Waxman et al., 1991) based on the blockade of autocrine loops. Normal muscle cells can be driven to proliferate or differentiate by a balance of opposing cellular signals (Florini and Magri, 1989; Olson, 1992) . Among them, growth factors can have intriguing effects: epidermal growth factor (EGF), basic fibroblast growth factor (bFGF) and transforming growth factor (TGF)-p are inhibitors of myogenic differentiation, even when used under non-mitogenic conditions, while insulin-like growth factors (IGFs) can either inhibit or stimulate myogenic differentiation depending on growth factor dosage (Florini and Magri, 1989; Olson, 1992) and exp- ression level of receptor (Quinn et al., 1993) . Autocrine growth factor loops can be expressed by rhabdomyosarcoma cells: bFGF (Schweigerer et al., 1987) and IGF-II (El-Badry et al., 1990; Minniti et al., 1992) are likely to be involved in the growth of these cells in vitro, but data on their possible role in the control of differentiation of myogenic neoplastic cells are still lacking. In this paper we report on the simultaneous production of different growth factors (IGF-II, bFGF, EGF, TGF-a) and receptors by human rhabdomyosarcoma cell lines. The effects exerted on proliferation and differentiation by antibodies directed to single autocrine loops were compared with those induced by suramin, a drug which non-selectively interferes with the binding to cellular receptors by heparin-binding growth factors as well as by other growth factors like EGF (Stein, 1993; Sachsenmaier et al., 1994) and therefore is expected to block all the autocrine circuits simultaneously.
Materials and meds
Cells and culture conditions Human rhabdomyosarcoma cell lines used were RD/ 18 and CCA, derived from tumours of the embryonal histotype , 1993 , and RMZ-RC2, derived from an alveolar rhabdomyosarcoma (Nanni et al., 1986 (Bell et al., 1984 Figure 2 shows the growth inhibition of all the cell lines at the same time point (4 days). In some cases slightly higher inhibitions were obtained at different time points (compare Figure 2 with insets of Figure 3) negative RMZ-RC2 cell line (Figure 2) . Specificity of the inhibition obtained with polyclonal anti-bFGF rabbit antiserum was assessed by running in parallel samples with non-immune rabbit serum: no effect on proliferation was observed (data not shown If multiple autocrine loops are likely to control both rhabdomyosarcoma growth and differentiation (including some not addressed in the present work), the simultaneous blocking of all the circuits possibly obtained by suramin might result in a better effect. In addition to the blocking of cell proliferation in CCA and RMZ-RC2 cells lines suramin, at the highest doses given, significantly increased the percentage of myogenic differentiated elements over untreated cells (Figure 4 and Table I ). RD/1 8 cells proved to be five times less sensitive than CCA and RMZ-RC2 to the antiproliferative action of suramin, and their differentiation was not stimulated.
Diomss
We found that human rhabdomyosarcoma cells can show a redundancy of growth-sustaining autocrine loops. The three rhabdomyosarcoma cell lines showed a very high level of IGF-II mRNA. in agreement with the high level of IGF-II protein reported to be present in supernatants of the RD cell line (El-Badry et al.. 1990) . from which the RD 18 clone had been derived (De Giovanni et al.. 1993) . Moreover. the three cell lines showed a high and comparable expression of IGF-I receptor. In normal myogenic cells IGF-II is probably the most important growth factor inducing both growth and differentiation (Florini and Magri; . Olson. 1992 . It is produced in all rhabdomyosarcoma tumours (Yun, 1992; Minniti et al., 1994) and plays a role in rhabdomyosarcoma cell proliferation (Kalebic et al.. 1994; Shapiro et al.. 1994 ). However, under particular conditions (high IGF-II doses or receptor overexpression) it could also inhibit myogenic differentiation (Florini and Magri. 1989; Quinn et al.. 1993) . We therefore analysed whether the blockade of this loop affects rhabdomyosarcoma cells. Cell proliferation was indeed inhibited but differentiation followed the same kinetics of control cultures and reached similar levels.
The two other possible autocnrne loops showed some differences among cell lines. bFGF mRNA and FGFreceptor were present in all the rhabdomyosarcoma lines studied, but only RD 18 cells showed a substantial growth inhibition after treatment with blocking antibody. The circuit based on the production of EGF TGF-a and of the common EGF receptor was absent in the RMZ-RC2 cell line, which did not express EGF receptor and TGF-a mRNA and was not affected by the presence of the anti-EGF receptor blocking antibody. The lack of EGF receptor could be related to its origin from the alveolar histotype. Treatment with antibodies to components of either bFGF or EGF TGF-a autocrine loops did not result in an increase in myogenic differentiation.
From these observations it can be concluded that in the human rhabdomyosarcoma model a decrease in cell growth is not per se sufficient to trigger myogenic differentiation. This conclusion is in agreement with findings obtained using drugs and other pharmacological treatments De Giovanni et al., 1993) .
Multiple autocrine circuits with inhibitory activity might simultaneously operate in the same cell. In order to obtain a simultaneous block of all the autocrine circuits, we tested the effect of suramin. a molecule which non-selectively interferes with the binding of growth factors to their cellular receptors (Stein, 1993; Sachsenmaier et al., 1994) . It has been found effective in inhibiting rhabdomyosarcoma proliferation (Minniti et al.. 1992; Kalebic et al., 1994) , but no data on differentiation were available so far. In our system suramin caused a marked growth inhibition of CCA and RMZ-RC2 cells and significantly increased the percentage of myosinpositive cells.
In contrast RD 18 cells displayed an entirely different behaviour: the dose of suramin required for 50% growth inhibition was about five times higher. and no induction of myogenic differentiation was obtained at any suramin dose. These results suggest the existence of two different mechanisms in the response of rhabdomyosarcoma cells to suranmn: a high affinity pathway, which mediates both growth inhibition and myogenic differentiation, as in CCA and RMZ-RC2. and a low affinity one which entails only growth inhibition. as in RD 18.
On the whole our results with blocking antibodies indicate that the effects of suramin on myogenic differentiation are not mediated by IGF-II. bFGF, or EGF TGF-a. An obvious possibility would be the existence of additional autocrine loops. but it must be taken into account also that suramin has pleiotropic effects. not limited to the interaction between growth factors and their receptors. but extended to other metabolic pathways (Stein. 1993) . Among these, the inhibition of protein kinase C (PKC) activity could be important in the myogenic system. PKC plays a role in the transduction of growth factor signals and seems to be crucial in the signal transduction pathways that inhibit myogenesis. Activated PKC can mimic the effect of FGF on the inhibition of muscle-specific gene activation (Li et al.. 1992) . Suramin can also inhibit topoisomerase II (Stein. 1993) . a pathway blockade shared with many antineoplastic drugs. We showed some years ago that some antimeoplastic drugs can indeed stimulate myogenic differentiation of rhabdomyosarcoma .
The use of suramin in preclinical studies led to some evidence of differentiation induction in other human tumours. such as colorectal cancer (Baghdiguian et al.. 1992 : Stein, 1993 : Lahm et al.. 1994 ) and hepatoma cells (Kraft et al.. 1993) . Induction of differentiation by suramin has also been reported in a dimethylbenzanthracene-induced rat rhabdomyosarcoma (Arnold and Salminen. 1993) . Our results suggest that suramin could hamper the growth of human rhabdomyosarcoma cells and favour their myogenic differentiation.
